198 related articles for article (PubMed ID: 35086141)
21. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
26. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
27. High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Vercellino L; Cottereau AS; Casasnovas O; Tilly H; Feugier P; Chartier L; Fruchart C; Roulin L; Oberic L; Pica GM; Ribrag V; Abraham J; Simon M; Gonzalez H; Bouabdallah R; Fitoussi O; Sebban C; López-Guillermo A; Sanhes L; Morschhauser F; Trotman J; Corront B; Choufi B; Snauwaert S; Godmer P; Briere J; Salles G; Gaulard P; Meignan M; Thieblemont C
Blood; 2020 Apr; 135(16):1396-1405. PubMed ID: 31978225
[TBL] [Abstract][Full Text] [Related]
28. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
29. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
30. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.
Roschewski M; Patel MR; Reagan PM; Saba NS; Collins GP; Arkenau HT; de Vos S; Nuttall B; Acar M; Burke K; White RD; Udriste M; Sharma S; Dougherty B; Stetson D; Jenkins D; Mortlock A; Forcina A; Munugalavadla V; Flinn I
Clin Cancer Res; 2023 Sep; 29(17):3301-3312. PubMed ID: 37364001
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
33. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
35. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Saburi M; Sakata M; Kodama Y; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
J Clin Exp Hematop; 2023 Sep; 63(3):201-204. PubMed ID: 37518271
[No Abstract] [Full Text] [Related]
36. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
37. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world.
Ionescu-Ittu R; Shang A; Velde NV; Guerin A; Lin Y; Shi L; Shi S; Qayum N
J Comp Eff Res; 2019 Oct; 8(13):1067-1075. PubMed ID: 31452397
[No Abstract] [Full Text] [Related]
38. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Park SI; Grover NS; Olajide O; Asch AS; Wall JG; Richards KL; Sobol AL; Deal AM; Ivanova A; Foster MC; Muss HB; Shea TC
Br J Haematol; 2016 Oct; 175(2):281-289. PubMed ID: 27448091
[TBL] [Abstract][Full Text] [Related]
40. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Gouni S; Rosenthal AC; Crombie JL; Ip A; Kamdar MK; Hess B; Feng L; Watson G; Ayers A; Neelapu SS; Khurana A; Lin Y; Iqbal M; Merryman RW; Strati P
Blood Adv; 2022 May; 6(9):2757-2762. PubMed ID: 35240681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
